SGI
CORT icon

Summit Global Investments’s Corcept Therapeutics CORT Stock Holding History

Summit Global Investments’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-59,682
Closed -$1.18M – 484
2021
Q4 		$1.18M Buy
+59,682
New +$1.21M 0.08% 212

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Global Investments's CORT Position: Q1 2022 in Review

Summit Global Investments sold out of Corcept Therapeutics (CORT) in Q1 2022, closing a stake of 59,682 shares — an estimated $1.18M sold.

Summit Global Investments first reported a position in CORT in Q4 2021 and held it in 1 quarter. The position peaked at $1.18M in Q4 2021. 228 funds tracked by Wall St. Rank hold CORT as of Q1 2022.

  • Summit Global Investments reported no remaining Corcept Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Summit Global Investments sold 59,682 Corcept Therapeutics shares in Q1 2022, an estimated $1.18M.
  • Summit Global Investments first reported a position in Corcept Therapeutics in Q4 2021 and held it in 1 quarter.
  • Summit Global Investments's Corcept Therapeutics position peaked at $1.18M in Q4 2021.
  • 228 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2022.

Based on Summit Global Investments's 13F filing for Q1 2022, filed 29 Apr 2022.